Nothing said here yet.
to join the conversation.
Positive Phase 2 ACUITY trial findings support Privosegtor’s potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyondZUG, Switzerland, October 29th, 2026 -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS)…
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective, complementary biological evidence of reduced neuroaxonal injury…
Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation ZUG, Switzerland, October 20, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical…
Markviss innritun sjúklinga með auknar líkur á meðferðarsvörun: 2/3 af þeim 176 sjúklingum sem innritaðir voru bera þann TNFR1-erfðabreytileika sem tengdur hefur verið aukinni klínískri svörun í fasa 2 rannsóknum.
High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials Precision Medicine Approach in a Large Market: Licaminlimab is positioned as a…
Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end ZUG, Switzerland, October 7, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS)…
Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life ZUG, Switzerland, October 1, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a…
Oculis Announces Resignation of Lionel Carnot from Board of Directors ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to…
Oculis Holding AG (OCS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
The mean of analysts' price targets for Oculis Holding AG (OCS) points to a 199.8% upside in the stock.